Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Flputnam Investment Management Co.

Flputnam Investment Management Co. lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 15.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,971 shares of the medical equipment provider’s stock after selling 561 shares during the period. Flputnam Investment Management Co.’s holdings in Intuitive Surgical were worth $1,002,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. RB Capital Management LLC grew its position in shares of Intuitive Surgical by 4.4% in the first quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 73 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Intuitive Surgical by 0.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock valued at $285,603,000 after purchasing an additional 5,233 shares during the period. Baird Financial Group Inc. grew its position in shares of Intuitive Surgical by 2.3% in the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock valued at $6,362,000 after purchasing an additional 481 shares during the period. Brown Brothers Harriman & Co. grew its position in shares of Intuitive Surgical by 576.7% in the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 346 shares during the period. Finally, Covestor Ltd grew its position in shares of Intuitive Surgical by 50.4% in the first quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 140 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 1.2 %

Shares of Intuitive Surgical stock opened at $374.17 on Thursday. The firm has a market cap of $132.62 billion, a P/E ratio of 74.39, a P/E/G ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The business has a 50-day moving average price of $387.56 and a 200 day moving average price of $342.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, beating the consensus estimate of $1.48 by $0.12. The company had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 earnings per share. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on ISRG shares. Citigroup lifted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James boosted their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Truist Financial boosted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 24th. Finally, StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $375.70.

Insider Activity

In other news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the completion of the transaction, the executive vice president now directly owns 189 shares in the company, valued at $69,958.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.